Equity Overview
Price & Market Data
Price: $2.32
Daily Change: $0.00 / 0.00%
Daily Range: $1.96 - $2.33
Market Cap: $165,393,920
Daily Volume: 805,203
Performance Metrics
1 Week: 8.41%
1 Month: -15.02%
3 Months: 25.41%
6 Months: 8.92%
1 Year: 21.47%
YTD: 25.41%
Company Details
Employees: 108
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis. It has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.